![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 08, 2015 11:47:44 AM
"We have made excellent progress in 2015 in strengthening our oncology focus at KaloBios," said Herb Cross, KaloBios' Chief Financial Officer and Interim Chief Executive Officer. "We continue to work to expand our portfolio of oncology programs in clinical development, most notably with the addition of a third oncology indication as a result of the July FDA clearance of our IND for KB003 in CMML. We continue to enroll patients in the KB004 Phase 2 program in MDS and MF, as well as evaluating additional potential oncology indications for KB004 including solid tumors where EphA3 is expressed. With several oncology indications either in development or moving into the clinic, and other potential indications under evaluation, we continue to be excited about the potential of our assets."
"Based on current enrollment rates, and with several additional clinical sites expected to commence enrollment in the coming months, the company expects enrollment to continue to accelerate. The drug continues to be well tolerated with the most commonly reported side effects being infusion reactions".
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM